摘要
目的探讨贝伐珠单抗联合化疗对晚期恶性黑色素肿瘤临床疗效的影响。方法将我院2013年5月—2019年5月接诊的72例晚期黑色素肿瘤患者按照随机数字表法分为A组(n=36)和B组(n=36),给予A组多西他赛和顺铂化疗治疗,B组在A组基础上联合贝伐珠单抗治疗,比较两组患者治疗前后黑色素瘤组织微血管密度(microvessel density,MVD)、内皮生长因子(vascular endothelial growth factor,VEGF)水平,运用诺丁汉健康问卷调查表(nottingham health questionnaire,NHP)评估两组患者治疗前后生活质量,比较两组临床疗效与不良反应。结果经治疗,B组患者MVD、VEGF水平均较治疗前显著下降,差异有统计学意义(均P<0.05),且显著低于A组治疗后水平,差异有统计学意义(均P<0.05);两组治疗后NHP评分均较治疗前显著降低,差异有统计学意义(均P<0.05),且B组显著低于A组,差异有统计学意义(均P<0.05);B组治疗有效率(66.67%)显著高于A组(30.56%),差异有统计学意义(P<0.05);两组不良反应发生率,差异有统计学意义(P>0.05)。结论贝伐珠单抗联合化疗治疗,可显著降低晚期恶性黑色素瘤患者MVD、VEGF表达水平,提高临床疗效,改善其生活质量且不增加不良反应。
Objective To investigate the clinical effect of bevacizumab combined with chemotherapy on advanced malignant melanoma.Methods 72 patients with advanced melanoma in our hospital from May 2013 to May 2019 were randomly divided into group A(n=36)and group B(n=36).Group A was treated with docetaxel and cisplatin,while group B was treated with bevacizumab on the basis of group A.The microvessel density(MVD)and vascular endothelial growth factor(VEGF)in melanoma tissues were compared between the two groups before and after treatment the quality of life was evaluated by nottingham health questionnaire(NHP)before and after treatment,and the clinical efficacy and adverse reactions were compared between the two groups.Results After treatment,MVD and VEGF levels in group B were significantly lower than those before treatment(all P<0.05),and were significantly lower than those in group A(all P<0.05);after treatment,NHP scores in both groups were significantly lower than those before treatment(all P<0.05),and those in group B were significantly lower than those in group A(all P<0.05);the effective rate in group B (66.67%) was significantly higher than that in group A (30.56%) (P < 0.05). There was no significant difference in the incidence of good reaction (P > 0.05). Conclusion Bevacizumab combined with chemotherapy can significantly reduce the expression of MVD and VEGF in patients with advanced malignant melanoma, improve the clinical efficacy, improve the quality of life, and do not increase adverse reactions.
作者
王悦申
张明影
WANG Yueshen;ZHANG Mingying(Oncology,Jilin People's Hospital,Jilin Jilin 132011,China;Dermatology,Jilin People's Hospital,Jilin Jilin 132011,China)
出处
《中国卫生标准管理》
2021年第15期101-104,共4页
China Health Standard Management
